Informe 2019 Sobre Tratamientos de Sarcoma de la ASCO ( Sociedad Americana de Oncologia Medica)
  • Informe 2019 Sobre Tratamientos de Sarcoma de la ASCO ( Sociedad Americana de Oncologia Medica)
  • 27 Febrero 2020

Informe 2019 Sobre Tratamientos de Sarcoma de la ASCO ( Sociedad Americana de Oncologia Medica)

Sarcomas and in particular soft tissue sarcomas are rare malignancies of mesenchymal origin comprising about 1 % of all adult cancers. Systemic therapies for locally advanced and metastatic disease have been restricted for decades to very few effective and approved agents such as doxorubicin and ifosfamide. However, new therapeutic strategies including new drug developments and registrations such as trabectedin, pazopanib and eribulin as well as numerous clinical trial options have recently enriched the therapeutic armamentarium in the treatment of patients with advanced soft tissue sarcomas. New therapies for the treatment benefit of sarcoma patients along with current results from this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31st to June 4th 2019 will be presented in the following “ASCO Conference Report 2019 - Sarcomas/GIST”.

https://www.sarcoma-patients.eu/en/docman/conference-reports/177-spaen-asco-report-2019/file

Colaboradores